CCCC Insider Trading Activity and SEC Form 4 Filings
CCCC insider trading summary
Over the past 12 months, insiders at C4 Therapeutics, Inc. (CCCC) reported 1 sale worth $22K by 1 insider and no open-market purchases on SEC Form 4. Net insider selling was $22K.
Latest CCCC insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 16, 2026 | Leonard Reyno | Chief Medical Officer | Sell | $22K (10,000 @ $2.22) |
| Feb 18, 2025 | Scott N Boyle | Chief Business Officer | Sell | $2K (669 @ $3.15) |
| Feb 14, 2025 | Scott N Boyle | Chief Business Officer | Sell | $2K (490 @ $3.15) |
| Feb 8, 2023 | Utpal Koppikar | Director | Buy | $32K (5,667 @ $5.60) |
| Apr 12, 2022 | Andrew Hirsch | President & CEO | Buy | $84K (10,000 @ $8.40) |
| Jan 4, 2022 | Adam Crystal | Chief Medical Officer | Sell | $34K (1,054 @ $32.66) |
| Jan 4, 2022 | Adam Crystal | Chief Medical Officer | Sell | $441K (13,946 @ $31.59) |
| Dec 17, 2021 | Malcolm Salter | Director | Sell | $23K (755 @ $30.25) |
| Nov 19, 2021 | Malcolm Salter | Director | Sell | $30K (755 @ $40.11) |
| Oct 15, 2021 | Malcolm Salter | Director | Sell | $34K (755 @ $44.94) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.